Simulect Injection

उत्पाद अवलोकन

About Simulect Injection

Simulect Injection is a medication containing the active ingredient Basiliximab, classified as Interleukin-2 Receptor Blocking Antibody. Basiliximab, sold under the brand name Simulect, is a monoclonal antibody used to prevent rejection in kidney transplants. It is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used in combination with other medicines used to prevent organ rejection.

Key Benefits & Uses

• Used for: INDICATIONS AND USAGE Simulect ® (basiliximab) is indicated for the prophylaxis of acute organ rejection in patients receiving renal transplantation.
• Use only as directed on the product label or by a healthcare professional.
• Follow the authorised product information for dosing and duration of use.

Active Ingredient & Action

Basiliximab, the active ingredient in Simulect Injection, belongs to the Interleukin-2 Receptor Blocking Antibody class. INDICATIONS AND USAGE Simulect ® (basiliximab) is indicated for the prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine, USP (MODIFIED), and corticosteroids. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking Simulect Injection. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use Simulect Injection for extended periods without medical advice.